Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salprep is a sulfate-based osmotic laxative solution indicated for bowel cleansing in preparation for colonoscopy. Developed by EA Pharma, it contains a combination of sodium sulfate anhydrous, magnesium sulfate hydrate, and potassium sulfate. The drug works by increasing the osmotic pressure within the intestinal tract, which inhibits the absorption of water and promotes the accumulation of fluid in the bowel lumen, resulting in a thorough purgative effect. This formulation is typically administered in a split-dose regimen to improve patient tolerability and ensure high-quality visualization of the colonic mucosa during endoscopic procedures. It was approved in Japan in 2021.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium sulfate + magnesium sulfate + potassium sulfate.